Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOT4: FLOT vs ECF in resectable gastric and esophagogastric junction adenocarcinoma
2010-018754-13Phase 2Completed
- Sponsor
- Krankenhaus Nordwest
- Start
- May 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of docetaxel, oxaliplatin, fluorouracil, epirubicin, cisplatin and 2 more in gastric adenocarcinoma and gastroesophageal adenocarcinoma (2 arms), sponsored by Krankenhaus Nordwest. Primary endpoint: Overall survival. Started May 2010; status: completed.
02
Drugs
docetaxeloxaliplatinfluorouracilepirubicincisplatin
03
Conditions
gastric adenocarcinomagastroesophageal adenocarcinoma
Beyond the preview
Go deeper on 2010-018754-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018754-13.